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Abstract: 
Background: 
NOD2/CARD15 polymorphisms have been identified as risk factors of both, Crohn´s disease 
and graft versus host disease (GvHD) following allogeneic stem cell transplantation. 
However, the role of these receptors of innate immunity in the pathophysiology of 
gastrointestinal GvHD is still poorly defined.  
Methods:  
Immunohistological features of intestinal GvHD were analyzed in gastrointestinal biopsies 
from 58 patients obtained at the time of first onset of intestinal symptoms and correlated the 
observed changes with concomitant risk factors and the presence of polymorphisms within the 
pathogen recognition receptor gene NOD2/CARD15.  
Results: 
Intestinal GvHD was associated with a stage dependent decrease in CD4-T cell infiltrates and 
an increase in CD8 T cells in the lamina propria; CD8 infiltrates correlated with extent of 
apoptosis and consecutive epithelial proliferation. Presence of NOD2/CARD15 variants in the 
recipient was associated with a significant loss of CD4 T cells: In a semiquantitative analysis, 
the median CD4 score for patients with wildtype NOD2/CARD15 was 1.1 (range 3), but only 
0.4 (range 2) for patients with variants (p 0.002). This observation was independent from 
severity of GvHD in multivariate analyses and could not be explained by the loss of FoxP3+ 
T cells.  
Conclusions: 
Our results suggest a loss of protective CD4 T cells in intestinal GvHD which is further 
enhanced by the presence of NOD2/CARD15 variants. Our study might help to identify more 
selective therapeutic strategies in the future. 
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Introduction: 
Gastrointestinal Graft-versus-Host disease (GvHD) is the most severe and life threatening 
manifestation of acute GvHD following allogeneic SCT in humans. Up to now the exact 
mechanisms triggering intestinal GvHD are poorly understood: As in inflammatory bowel 
disease (IBD) (1;2) it is likely that the interaction of the intestinal flora with epithelial 
immune responses contributes to inflammatory signals that enhance the alloresponse. The first 
strong evidence was provided by van Bekkum in 1974 when  he reported that mice grown 
under germfree conditions almost failed to develop GvHD after transplantation of marrow and 
developed only delayed  GvHD if a higher T cell number by adding splenocytes was infused 
(3). Today, it is well accepted, that triggering antigen presenting cells (APC) by pathogen 
associated microbial patterns (PAMPs) via Toll-like receptors (TLRs) and a large set of 
further receptors is an important first step in inflammation in both, IBD and GvHD, and 
contributes to the initiation of an alloreaction in target organs of GvHD (4). 
Our group added the observation, that feeding of mice with lactobacilli dampened intestinal 
inflammation and indeed altered the severity and time course of intestinal GvHD; in addition, 
lactobacilli prevented translocation of intestinal bacteria to mesenteric lymph nodes (5). More 
recently, we demonstrated that single nucleotide polymorphisms (SNPs) within an important 
receptor of innate immunity, the intracytoplasmatic NOD2/CARD15, were associated with an 
increased risk of severe GvHD, treatment related mortality (6;7) and further transplant related 
complications like bronchiolitis obliterans (8). These associations suggest a further link in the 
pathophysiology of Crohn´s disease and intestinal GvHD, at least with regard to initial 
inflammation, and  may explain a clinically well known but yet unexplained individual 
susceptibility. 
Functional consequences of NOD2/CARD15 variants in humans have been shown both, in 
vitro and ex vivo in patients with inflammatory bowel disease: Isolated monocytes and 
dendritic cells showed a reduced capacity to release inflammatory cytokines in the presence of 
NOD2/CARD15 variants (9;10), epithelial cells revealed a deficient clearance of bacteria (11) 
and most important for antibacterial defence, Wehkamp and colleagues reported a strong 
reduction of human beta-defensin-2 production in epithelial cells (12).  
In contrast, data on the functional relevance of NOD2/CARD15 SNPs in allogeneic SCT have 
not yet been reported. We now tested the hypothesis, that immunohistological features of 
intestinal GvHD reflecting different pathophysiological cellular functions might be altered by 
the presence of NOD2/CARD15 variants in recipients or donors. In a prospective study we 
examined  gastrointestinal biopsies from 58 patients and found  a major impact of 
NOD2/CARD15 on CD4 T cell infiltrates. 
Material & Methods: 
Patient characteristics: 
A total of 64 patients receiving an allogeneic peripheral stem cell graft were included. 
Immunosuppressive prophylaxis consisted of ciclosporin followed by a short course of MTX 
in pts receiving standard conditioning and ciclosporin and MMF or MTX (n=3) in patients 
receiving reduced intensity regimens. Further patient characteristics are given in table 1. 
 
Intestinal biopsies: 
In 6 patients, endoscopy was performed prior to transplantation because of a history of 
previous inflammatory bowel disease or acute gastroenteritis during preceding treatment. In 
the remaining 58 patients, biopsies from the lower gastrointestinal tract were obtained after 
allogeneic SCT at the time of first symptoms indicating intestinal GvHD. As intestinal 
symptoms occurred frequently after onset of skin GvHD or at the time of tapering of 
immunosuppressive treatment for previous GvHD in other organs, the majority of patients 
was on treatment with corticosteroids at the time of biopsy, and 15 patients have been pre-
treated with additional etanercept (n=4), ATG (n=5) or both (n=6). Clinical gastrointestinal 
GvHD was graded according to Glucksberg as modified by the 1994 consensus conference, 
and biopsies were grouped according to clinical stage of intestinal GvHD at the time of 
biopsies if histology confirmed GvHD. Infections were excluded by microbiological analysis 
of stool samples and by quantitative PCR for adeno-, CMV and HHV6 viruses in biopsies and 
blood. 
Biopsies obtained from unaffected areas of surgical specimens obtained during resection of 
localized tumors served as controls. 
 
Histological and immunohistological analysis: 
Tissue biopsies were fixed in 4% buffered formalin for at least 24 hours and embedded in 
paraffin. Sections of approximately 2-3µm thickness were cut from tissue blocks and stained 
with haematoxylin and eosin according to standard protocols. Histopathological analysis was 
performed without knowledge of the clinical data, specimens were examined in random order. 
Common histopathological features of GvHD like epithelial apoptosis, loss of crypts and 
cellular infiltrates for neutrophils, eosinophils and lymphocytes in general, were assessed 
separately for the epithelial area and the lamina propria.  
Immunohistochemical studies were performed for the expression of CD4, CD8, CD68, 
MIB1a and FoxP3 using an avidin-biotin peroxidase method with diaminobenzidine (DAB) 
chromogen. After antigen retrieval by microwave treatment immunohistochemistry was 
carried out in a NEXES immunostainer (Ventana Medical Systems. Tucson, Arizona, USA) 
according to the manufacturer´s instructions. As primary antibodies, mouse monoclonal 
antibodies were used at a dilution of 1:5 for CD4 (Ventana No 250-2712), undiluted for CD8 
(Ventana No. 760-4250), at a dilution of 1:100 for the macrophage marker CD68 (Dako 
MO876), at a dilution of 1:50 for the proliferation marker Mib1 (Dako M7240) and at a 
dilution of 1:100 for FoxP3 (eBioscience No 14-4777-80). After incubation for 24 hrs at 37°C 
slides were rinsed in phosphate buffered saline and incubated with the second antibody (rabitt 
anti.mouse, 1:500, Ventana Medical System) for two hours at room temperature. Antibody 
binding was visualized with 0.05% DAB (Ventana Medical System) and 0.01% hydrogen 
peroxide. The material was rinsed in phosphate buffered saline and counterstained with 
hematoxyline.  
 
Statistical analysis: 
A semiquantitative score was chosen for reporting immunohistological analyses and 
histological changes: Scoring of infiltrates ranged from 0 to 3, score 0 indicating only 0-1 
cells/ high power field (HPF); score 1 indicating 2-4 cells, score 2 indicating 5-7 and score 3 
8-10 cells/HPF. At least 10 HPFs were analyzed per section, and if available, at least 2 
sections were analysed per biopsy. A final median score was listed for comparison of 
individual biopsies. For statistical analyses, the grouped median and range were calculated; 
comparisons between groups were made by non-parametric Wilcoxon tests. For multivariate 
analyses, binary logistic regression was performed for low CD4 infiltrates (score 0 versus 
scores 1-3) and low neutrophil infiltrates (score 0 versus scores 1-2).   
 
Ethical considerations: 
All patients gave written informed consent to perform additional biopsies for research use. 
The protocol had been approved by the local ethical committee at the University of 
Regensburg Medical Centre. 
 
Results: 
Comparison of biopsies obtained after allogeneic SCT and controls 
In contrast to controls, post transplant biopsies showed as expected an increase in epithelial 
apoptosis and a loss of crypts. Eosinophils and neutrophils were more prominent in post 
transplant biopsies. There was a trend for an increased CD8 infiltrate whereas both, CD4 and 
FoxP3 positive cells were significantly reduced following SCT. Lamina propria macrophages 
seemed to be less affected (Tab 2). When we analyzed the correlation of apoptosis with 
cellular infiltrates, there was a strong association between CD8 cells in the lamina propria and 
apoptosis (r = 0.78, p 0.002) suggesting that cytotoxic T cells might be the major effector 
cells of intestinal damage. Epithelial proliferation as indicated by MIB1 staining was 
increased following SCT and might reflect compensatory epithelial repair. The 6 patients 
analyzed prior to SCT showed intermediate changes with minor cellular infiltrates and 
absence of apoptosis (data not shown). 
 
 
Loss of CD4 cells and neutrophils in severe GvHD 
Only 4 patients had no evidence of GvHD in histology and recovered clinically, 32 had stage 
1 and 2 and 22 stage 3 and 4 intestinal GvHD, confirmed by histology in all of them. To 
assess the impact of GvHD severity on histological changes, patients were grouped according 
to the clinical severity of intestinal GvHD (stage 0-2 versus stage 3 and 4) at the time of 
biopsy (table 3). Patients with severe GvHD had the lowest CD4- and neutrophil infiltrates, 
whereas the highest CD4 score was observed in the few patients without and those with stage 
1 GvHD: Median CD4 infiltrates were scored 1.1 (range 3) in patients with GvHD 0-2 and 
dropped to a score of 0.4 (range 1) in patients with severe GvHD (p< .002). Median CD4 
density in the few patients without GvHD was scored 1.3 (range 2) confirming the stage 
dependent loss of CD4 cells (data not shown). Similar changes were seen for the neutrophil 
infiltrate, whereas all other parameters showed only trends (e.g. for a further increase of CD8 
cells or a decrease of FoxP3 cells). To assess further the role of FoxP3 positive cells, we 
calculated the FoxP3/CD4 and FoxP3/CD8 ratio in all posttransplant biopsies. Whereas there 
was no difference for FoxP3/CD4 ratio between patients with mild and moderate GvHD, the 
FoxP3/CD8 ratio decreased from 0.8 (standard error 0.2) in mild to 0.4 (SE 0.1) in more 
severe GvHD with borderline significance (p 0.05). 
 
Factors affecting CD4 and neutrophil infiltrates 
As patients were at different phases of their clinical GvHD and under different intensity of 
immunosuppressive treatment we next checked whether confounding treatment or patient 
parameters had an impact on  the observed changes in CD4 and neutrophil counts. In addition, 
we addressed the hypothesis that the NOD2/CARD15 status could affect the histological and 
pathophysiological manifestation of GvHD. Among pre-transplant factors, neither the type of 
donor, the intensity of conditioning, age or underlying disease had any impact on CD4 and 
neutrophil infiltrates. Surprisingly, the recipient NOD2/CARD15 status had a dramatic impact 
on CD4 cells, as the CD4 score dropped from a median of 1.1 (3) in patients with wildtype 
NOD2/CARD15 to a score of 0.4 (1) in patients with presence of variants (p 0.002) (figure 1). 
This decline in CD4 cells was seen in both subgroups, patients with mild and patients with 
severe gastrointestinal (GI-)GvHD (table 4). A similar but not significant trend was seen for 
the neutrophil counts. In contrast, donor NOD2/CARD15 status had a stronger influence on 
neutrophil infiltrates: Neutrophil density was 0.5 (1) in wildtype donors but only 0.0 (1) in 
donors with NOD2/CARD15 variants (p<.0.05, data not shown). There was no significant 
impact of donor NOD2/CARD15 status on CD4 cell  infiltrates. 
Among the posttransplant factors, use of corticosteroids resulted in a significant suppression 
of CD4 cells and a marginal reduction of neutrophils: Median CD4 density was 1.0 (2) in 
patients with low dose or without steroids while it dropped to 0.5 (1) in patients with high 
dose steroids (exceeding 1 mg/kg prednisolone) (p< 0..02). Neutrophil density was lower in 
patients with high dose steroids (score 0.4 (1)) versus score 0.8 (1) in pts with low dose 
steroids (p  < 0-.04). In addition, CD4 cells were influenced by the additional use of T cell 
antibodies or etanercept (data not shown). Concomitant viral infections with a low number of 
copies were detected in 11 patients (CMV n=4, HHV6 n=7), but in none of the biopsies 
histology indicated viral disease as the leading cause of gastrointestinal damage. In addition, 
presence of viruses was equally distributed among patients with mild (36%) and patients with 
severe GvHD (43%), and presence of viruses did not affect immunohistological features of 
biopsies. 
As NOD2/CARD15 had been shown to affect the severity of GvHD, and the use of high dose 
steroids as well as antibodies also reflect the extent of clinical GvHD at the time of biopsy a 
multivariate analysis was performed addressing these factors. For low neutrophil density, 
none of the factors remained significant. For CD4 density, however, the recipient 
NOD2/CARD15 status remained the only highly significant factor with an odds ratio of 0.02 
for pts without NOD2/CARD15 variants (95% confidence interval 0.01 – 0.32, p  < .002). 
 
Discussion: 
 
Our study revealed both, confirmatory and new aspects of immunohistopathological changes 
of gastrointestinal GvHD.  
As reported in several studies (13-15), severe acute GvHD was accompanied by an increase in 
apoptotic epithelial cells which correlated with cytotoxic CD8 T cell infiltrates. By adding a 
marker of epithelial proliferation, we were able to demonstrate a compensatory attempt of 
epithelial repair. As previously published by some groups, CD4 infiltrates were even more 
reduced in severe GvHD resulting in a shift of the CD4/CD8 ratio towards CD8 (15-17). 
Staining for FoxP3, a marker of regulatory T cells, revealed a parallel decrease of FoxP3 cells 
after SCT which seemed to be more pronounced in severe GvHD; indeed the FoxP3/CD8 
ratio was significantly lower in pts with severe GvHD. Thus, our findings are  is in line with a 
recent observation of Rieger and co-workers (18). However, the overall loss of CD4+ T cells 
was even more pronounced than that of the FoxP3+ subpopulation, suggesting that a 
preferential loss of FoxP3+ cells does not solely account for the occurrence of GvHD. As we 
did not perform double staining in this pilot study, this discrepancy may also be explained by 
further FoxP3 positive cells beyond CD4 cells such as FoxP3 positive CD8 cells, which have 
been reported both in experimental models and in biopsies from organ transplant recipients 
(19;20). 
A second finding not reported in previous studies was suppression of neutrophil infiltrates in 
severe GvHD. As our biopsies were not obtained at identical time points in relation to the 
initiation of GvHD treatment, actual immunosuppressive treatment might result in indirect 
effects, and this was clearly confirmed for high dose corticosteroid treatment and the use of 
monoclonal agents.  
An unexpected and initially surprising observation was the clear impact of NOD2/CARD15 
SNPs on the cellular infiltrate: Donor NOD2/CARD15 status affected the neutrophil infiltrate, 
but this was not significant in multivariate analysis. Neutrophil recruitment is the main effect 
of the chemokine IL8, which is a typical cytokine induced by a NOD2/CARD15 dependent 
activation of NFkB and is used as a functional readout for intact NOD2/CARD15 signalling 
in many studies (9).  
Recipient NOD2/CARD15 status was associated with a severe reduction of CD4 cells which 
was observed independent from the severity of GvHD and remained the only significant 
factor in the multivariate analysis. Interestingly, similar results are found  in an ongoing study 
on skin biopsies suggesting that the interaction of NOD2/CARD15 and CD4 might be a 
general biological phenomenon in epithelial tissues. Although these findings need 
confirmation in a prospective trial with a more homogenous population of untreated GvHD, 
there are several recent data supporting that NOD2/CARD15 might be involved in the 
recruitment of CD4 cells in epithelial tissues: An important population in intestinal 
inflammation are the TH17 cells, which have been shown to have either detrimental or 
protective effects in different animal models of GvHD (21-23). So far, human data on TH17 
cells in intestinal GvHD are missing. Interestingly, APCs seem to produce IL23 and induce 
TH17 in a NOD2/CARD15 dependant manner (24) and therefore, different recruitment of 
TH17 cells might play a role. A further chemokine involved in APC recruitment of memory T 
cells is MIP3alpha, which is also produced under the control of NOD2/CARD15 (G Rogler, 
unpublished data): Thus recruitment of antigen-specific memory cells involved in 
antibacterial defence against commensal bacteria might be disturbed in the presence of 
NOD2/CARD15 SNPs. A direct link between regulatory T cells and NOD2/CARD15 has not 
been reported so far. Ongoing studies try to clarify whether epithelial factors (thymic stromal 
lymphopoetin, TSLP, 25) or APC factors (such as retinoid acid, 26) involved in recruitment of 
regulatory T cells are produced in a NOD2/CARD15 dependent manner. The exact 
contribution  of regulatory T cells, memory cells and TH17 cells to the observed decrease of 
CD4 cells is now analyzed in ongoing projects. A major role of NOD2/CARD15 in APCs 
rather than epithelial cells in the setting of GvHD is also suggested by the recently published 
study on NOD2/CARD15 knockout mice, where only the defect in host haematopiesis derived 
cells (including APCs) accelerated GvHD (27). 
Our findings need clearly confirmation in a larger study including biopsies prior to initiation 
of immunosuppressive treatment of GvHD in order to exclude indirect effects of concomitant 
medication. However, they point to two important aspects: First, the significant loss of CD4 in 
more severe GvHD suggests, that intestinal CD4 cells play an important role in 
immunological homeostasis preventing uncontrolled inflammation against intestinal bacteria. 
Here, in GvHD pathophysiological interactions initiating a pathological immune response 
might be quite similar to inflammatory bowel disease whereas the effector phase with damage 
by alloreactive T cells is clearly different. 
Finally, our current immunosuppressive strategies deplete T-cell populations rather 
unselectively and therefore might even worsen the loss of immunomodulatory CD4 T cell 
populations. This observation might explain why so far any type of second line treatment of 
GvHD results in equal unsatisfactory results with almost only 30% of pts becoming long term 
survivors. In addition, the link of NOD2/CARD15 SNPs and intestinal CD4 infiltrates 
provides direct evidence for the relevance of innate immune mechanisms for the  recruitment 
of specific and adaptive effector cells. A more precise insight in the interaction of Toll-like 
(TLRs) and NOD-like (NLRs) receptors, activation of APCs and subsequent recruitment of T 
cell subpopulations might open more selective or even organ specific strategies to manipulate 
GvHD in the future. 
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Table 1: Patient characteristics.  
MUD = matched unrelated donor, RIC = reduced intensity conditioning; D = donor, R = 
recipient 
 
 
 Posttransplant 
(n=58) 
Age at SCT  
(years, +/- SE) 
48 (3) 
Underlying disease: 
Acute leuk. 
Myeloprolifer.dis. 
Lymphoma 
myeloma 
 
30 
12 
12 
4 
Donor: 
HLAid.sibl. 
MUD 
 
28 
30 
Conditioning: 
Standard 
RIC 
 
19 
39 
NOD2/CARD15 
status: 
D & R wildtype 
R variant: 
SNP 8/12/13 
D variant 
SNP8/12/13 
R& D variant; 
SNP8/12/13 
 
 
29 
129/3/013 
6/1/2 
4 
2/0/2 
Table 2: Comparison of (immuno-) histological changes in controls and patients after 
allogeneic stem cell transplantation. Median (immune-)histological changes and ranges 
are given. Wilcoxon texts were performed to define significant changes. LP = Lamina 
propria. FoxP3 = marker of regulatory T cells; MIB 1 = epithelial proliferation, CD68 = 
macrophage marker. 
 
 
 
 
 
 
 Control 
(n=12) 
Pts after SCT 
(n=58) 
 
Apopt. Nuclei 0.1 (1) 0.8 (3) 0.03 
Loss of crypts 0 (0) 1.0 (3) 0.05 
Eosinophils 
LP 
0.2 (2) 0.7 (3) 0.02 
Neutrophils 
LP 
0 (1) 0.4 (2) 0.08 
CD4 LP 1.7 (1) 0.8 (3) 0.000 
FoxP3 pos 
cells LP 
1.1 (2) 0.5 (2) 0.02 
CD8 LP 1.0 (0) 1.4 (3) 0.06 
MIB1 1.1 (1) 1.6 (3) 0.05 
CD68 LP 1.3 (1) 1.4 (1) Ns 
Table 3: Severity of clinical gastrointestinal (GI) GvHD at the time of biopsy and 
(immuno)-histological changes. Median (immune-)histological changes and ranges are 
given. Wilcoxon texts were performed to define significant changes. LP = Lamina 
propria. FoxP3 = marker of regulatory T cells; MIB 1 = epithelial proliferation, CD68 = 
macrophage marker. 
 
 GI-GvHD 0-2 
(n=17) 
GI-GvHD 3-4 
(n=41) 
 
Apoptotic nuclei 0.5 (3) 0.9 (2) Ns 
Loss of crypts 0.9 (3) 1.3 (2) Ns 
Eosinophils LP 0.7 (2) 0.5 (2) Ns 
Neutrophils LP 0.4 (2) 0.05 (1) 0.01 
CD4 LP 1.1 (3) 0.4 (1) 0.002 
FoxP3 pos cells 
LP 
0.5 (2) 0.3 (1) Ns 
CD8 LP 1.2 (2) 1.6 (3) Ns 
MIB1 1.4 (2) 1.7 (3) Ns  
CD68 LP 1.4 (1) 1.3 (1) Ns 
 
 
 
 
 
 
 
 
 
 
 
Table 4: Recipient (R) NOD2/CARD15 status affects median CD4 infiltrate independent 
from severity of GvHD. Variant = Presence of any NOD2/CARD15 SNP. Median CD4 
infiltrates (+/- SE) are shown. Recipient NOD2/CARD15 status was the only significant 
factor affecting CD4 infiltrate in multivariate logistic regression analysis. 
 
 
 R wildtype (n=40) R variant (n=19) 
GI-GvHD 0  - 2 
(n=17) 
1,27 
(0.2) 
N=14 
0.50 
(0.2) 
N=3 
GI-GvHD  3 / 4 
(n=41) 
0.57 
(0.1) 
N=25 
0.27 
(0.1) 
N=16 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Recipient NOD2/CARD15 status affects CD4 infiltrates. Biopsies obtained post 
transplant were grouped according to absence (wildtype) or presence (variant) of any 
NOD2/CARD15 SNPs. Median (immune-)histological changes (-/+ SE) are shown. 
Wilcoxon tests were performed to define significant changes. LP = Lamina propria. 
FoxP3 = marker of regulatory T cells; MIB 1 = epithelial proliferation, CD68 = 
macrophage marker. 
 
 
 
 
 
